Fiera Capital Corp Cuts Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Fiera Capital Corp trimmed its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 5.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,037,248 shares of the biopharmaceutical company’s stock after selling 175,313 shares during the period. Fiera Capital Corp’s holdings in Amicus Therapeutics were worth $28,611,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of FOLD. Stephens Inc. AR acquired a new stake in Amicus Therapeutics in the 4th quarter valued at $101,000. Choreo LLC purchased a new stake in shares of Amicus Therapeutics in the fourth quarter worth about $103,000. Tempus Wealth Planning LLC acquired a new stake in shares of Amicus Therapeutics in the fourth quarter valued at about $259,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Amicus Therapeutics by 11.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 63,358 shares of the biopharmaceutical company’s stock valued at $597,000 after buying an additional 6,314 shares during the period. Finally, R Squared Ltd acquired a new position in Amicus Therapeutics during the 4th quarter worth approximately $79,000.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at approximately $8,884,273.08. This represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.20% of the stock is currently owned by corporate insiders.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD opened at $9.64 on Friday. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $2.88 billion, a price-to-earnings ratio of -28.35, a price-to-earnings-growth ratio of 1.69 and a beta of 0.61. Amicus Therapeutics, Inc. has a twelve month low of $8.78 and a twelve month high of $14.03. The business has a 50 day simple moving average of $9.60 and a 200-day simple moving average of $10.43.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on FOLD. Bank of America lifted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. Guggenheim boosted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. StockNews.com upgraded Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Finally, JPMorgan Chase & Co. raised their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, November 12th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Amicus Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $16.88.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.